476 related articles for article (PubMed ID: 9797136)
1. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
Patrick TA; Kranz DM; Zachary JF; Roy EJ
Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
[TBL] [Abstract][Full Text] [Related]
2. Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate.
Roy EJ; Cho BK; Rund LA; Patrick TA; Kranz DM
Int J Cancer; 1998 May; 76(5):761-6. PubMed ID: 9610737
[TBL] [Abstract][Full Text] [Related]
3. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis.
Kranz DM; Patrick TA; Brigle KE; Spinella MJ; Roy EJ
Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9057-61. PubMed ID: 7568072
[TBL] [Abstract][Full Text] [Related]
4. Bispecific agents target endogenous murine T cells against human tumor xenografts.
Rund LA; Cho BK; Manning TC; Holler PD; Roy EJ; Kranz DM
Int J Cancer; 1999 Sep; 83(1):141-9. PubMed ID: 10449621
[TBL] [Abstract][Full Text] [Related]
5. A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors.
Gawlick U; Kranz DM; Schepkin VD; Roy EJ
Bioconjug Chem; 2004; 15(5):1137-45. PubMed ID: 15366970
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics.
Thompson S; Dessi J; Self CH
MAbs; 2009; 1(4):348-56. PubMed ID: 20068406
[TBL] [Abstract][Full Text] [Related]
7. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen.
Schell TD; Tevethia SS
J Immunol; 2001 Dec; 167(12):6947-56. PubMed ID: 11739514
[TBL] [Abstract][Full Text] [Related]
8. Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice.
Patrick TA; Kranz DM; van Dyke TA; Roy EJ
J Neurooncol; 1997 Apr; 32(2):111-23. PubMed ID: 9120540
[TBL] [Abstract][Full Text] [Related]
9. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.
Cho BK; Roy EJ; Patrick TA; Kranz DM
Bioconjug Chem; 1997; 8(3):338-46. PubMed ID: 9177839
[TBL] [Abstract][Full Text] [Related]
10. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
13. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Haagen IA
Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
[TBL] [Abstract][Full Text] [Related]
14. IL-12 treatment of endogenously arising murine brain tumors.
Roy EJ; Gawlick U; Orr BA; Rund LA; Webb AG; Kranz DM
J Immunol; 2000 Dec; 165(12):7293-9. PubMed ID: 11120864
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor cells with bispecific antibodies and T cells.
Kranz DM; Manning TC; Rund LA; Cho BK; Gruber MM; Roy EJ
J Control Release; 1998 Apr; 53(1-3):77-84. PubMed ID: 9741915
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.
Schell TD; Mylin LM; Georgoff I; Teresky AK; Levine AJ; Tevethia SS
J Virol; 1999 Jul; 73(7):5981-93. PubMed ID: 10364350
[TBL] [Abstract][Full Text] [Related]
17. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
Root AR; Guntas G; Katragadda M; Apgar JR; Narula J; Chang CS; Hanscom S; McKenna M; Wade J; Meade C; Ma W; Guo Y; Liu Y; Duan W; Hendershot C; King AC; Zhang Y; Sousa E; Tam A; Benard S; Yang H; Kelleher K; Jin F; Piche-Nicholas N; Keating SE; Narciandi F; Lawrence-Henderson R; Arai M; Stochaj WR; Svenson K; Mosyak L; Lam K; Francis C; Marquette K; Wroblewska L; Zhu HL; Sheehan AD; LaVallie ER; D'Antona AM; Betts A; King L; Rosfjord E; Cunningham O; Lin L; Sapra P; Tchistiakova L; Mathur D; Bloom L
MAbs; 2021; 13(1):1850395. PubMed ID: 33459147
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
19. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract][Full Text] [Related]
20. Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
Mandikian D; Takahashi N; Lo AA; Li J; Eastham-Anderson J; Slaga D; Ho J; Hristopoulos M; Clark R; Totpal K; Lin K; Joseph SB; Dennis MS; Prabhu S; Junttila TT; Boswell CA
Mol Cancer Ther; 2018 Apr; 17(4):776-785. PubMed ID: 29339550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
